REGENECYTE cord blood cell therapy in post-COVID syndrome: a phase IIa randomized, placebo-controlled trial

Authors

Institutions

Publication Details

Journal
EClinicalMedicine
Published
2026-01-01
DOI
https://doi.org/10.1016/j.eclinm.2025.103737
Primary Topic
Mesenchymal stem cell research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

REGENECYTE cord blood cell therapy in post-COVID syndrome: a phase IIa randomized, placebo-controlled trial

Jonas Wang, Joseph Rosenthal, Tong-Young Lee, Lung-Kuo Tai et al.
EClinicalMedicine
Mesenchymal stem cell research
article

REGENECYTE cord blood cell therapy in post-COVID syndrome: a phase IIa randomized, placebo-controlled trial

Jonas Wang, Joseph Rosenthal, Tong-Young Lee, Lung-Kuo Tai, Ernest Yin Lun Lau, Yu-Chin Su, Ying-Chieh Chen, Yen-Wen Huang
article en

Abstract

No abstract available for this paper.
EClinicalMedicineVol. 91
Mackay Medical University (TW), City of Hope (US), Applied Sciences Laboratory (United States) (US)
StemCyte, National Taiwan University Hospital, National Taiwan University
Good health and well-being
Openalex Percentile: Top 92%
Mesenchymal stem cell research
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.